Promoting osteoblast-mediated bone formation: a more promising approach for natural products to treat osteoporosis

Abstract

Osteoporosis is a systemic skeletal disorder characterized by reduced bone mass, compromised bone microstructure, and an increased risk of fractures, primarily due to excessive osteoclast-mediated bone resorption relative to osteoblast-mediated bone formation. While current anti-osteoporosis drugs, such as bisphosphonates and denosumab, predominantly focus on reducing bone resorption, osteoanabolic approaches are essential for restoring bone microarchitecture and ultimately reducing fracture risk. Traditional Chinese medicines (TCMs) and their active ingredients have long been used in China for osteoporosis prevention and treatment. This review provides a comprehensive evaluation of the effects and molecular mechanisms of 65 natural products across 24 categories on osteoblast-mediated bone formation. These compounds promote bone formation by regulating key transcription factors (RUNX2 and Osterix) and signaling pathways, including WNT/β-catenin, bone morphogenic protein (BMP), mitogen-activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B (PI3K/AKT), oxidative stress, autophagy, and epigenetic regulation. Notably, certain natural products [e.g., icariin (ICA)] exert their effects through multiple targets and pathways. Many of these natural products have demonstrated significant therapeutic efficacy in animal models, such as ovariectomized (OVX) mice. Our findings suggest that natural products with kidney-tonifying, anti-inflammatory, and antioxidant properties, as well as those inhibiting adipocyte differentiation, may hold promise for osteoporosis treatment. Additionally, we highlight current research gaps and propose future directions, including high-throughput screening and validation in diverse animal models, development of novel bone-targeting delivery systems, and identification of natural compounds targeting osteocytes.

Keywords

Natural products / Osteoblasts / Bone formation / Osteoporosis

Funding

This work was supported by the National Natural Science Foundation of China (No. 31800059).

Supporting information

Supporting information for this work can be obtained by contacting the corresponding authors via E-mail.

Declaration of competing interest

The authors declare no competing financial interests.

References

[1] Karsenty G. The complexities of skeletal biology. Nature. 2003; 423(6937):316-318. https://doi.org/10.1038/nature01654.

[2] Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011; 377(9773):1276-1287. https://doi.org/10.1016/S0140-6736(10)62349-5.

[3] Amarnath SS, Kumar V, Das SL. Classification of osteoporosis. Indian J Orthop. 2023; 57(Suppl 1):49-54. https://doi.org/10.1007/s43465-023-01058-3.

[4] Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019; 393(10169):364-376. https://doi.org/10.1016/S0140-6736(18)32112-3.

[5] Papadopoulou SK, Papadimitriou K, Voulgaridou G, et al. Exercise and nutrition impact on osteoporosis and sarcopenia—the incidence of osteosarcopenia: a narrative review. Nutrients. 2021; 13(12):4499. https://doi.org/10.3390/nu13124499.

[6] Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-1733. https://doi.org/10.1007/s00198-006-0172-4.

[7] Salari N, Ghasemi H, Mohammadi L, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021; 16(1):609. https://doi.org/10.1186/s13018-021-02772-0.

[8] Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1):136. https://doi.org/10.1007/s11657-013-0136-1.

[9] Carletti A, Gavaia PJ, Cancela ML, et al. Metabolic bone disorders and the promise of marine osteoactive compounds. Cell Mol Life Sci. 2023; 81(1):11. https://doi.org/10.1007/s00018-023-05033-x.

[10] Khosla S, Shane E. A crisis in the treatment of osteoporosis. J Bone Miner Res. 2016; 31(8):1485-1487. https://doi.org/10.1002/jbmr.2888.

[11] Patel DV, Horne A, House M, et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013; 120(4):773-776. https://doi.org/10.1016/j.ophtha.2012.10.028.

[12] Robinson DE, Ali MS, Pallares N, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis. J Bone Miner Res. 2021; 36(5):820-832. https://doi.org/10.1002/jbmr.4235.

[13] Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled freedom trial and its extension. J Bone Miner Res. 2018; 33(2):190-198. https://doi.org/10.1002/jbmr.3337.

[14] Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297(13):1465-1477. https://doi.org/10.1001/jama.297.13.1465.

[15] Yavropoulou MP, Makras P, Anastasilakis AD. Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother. 2019; 20(10):1201-1210. https://doi.org/10.1080/14656566.2019.1615882.

[16] Miller SA, St OE, Whalen KL. Romosozumab: a novel agent in the treatment for postmenopausal osteoporosis. J Pharm Technol. 2021; 37(1):45-52. https://doi.org/10.1177/8755122520967632.

[17] Tabacco G, Bilezikian JP. Osteoanabolic and dual action drugs. Br J Clin Pharmacol. 2019; 85(6):1084-1094. https://doi.org/10.1111/bcp.13766.

[18] Seeman E, Martin TJ. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol. 2019; 15(4):225-236. https://doi.org/10.1038/s41584-019-0172-3.

[19] Gao Z, Lu Y, Halmurat U, et al. Study of osteoporosis treatment principles used historically by ancient physicians in Chinese medicine. Chin J Integr Med. 2013; 19(11):862-868. https://doi.org/10.1007/s11655-013-1328-z.

[20] Duan Y, Su YT, Ren J, et al. Kidney tonifying traditional Chinese medicine: potential implications for the prevention and treatment of osteoporosis. Front Pharmacol. 2023; 13:1063899. https://doi.org/10.3389/fphar.2022.1063899.

[21] Zhang ND, Han T, Huang BK, et al. Traditional Chinese medicine formulas for the treatment of osteoporosis: implication for antiosteoporotic drug discovery. J Ethnopharmacol. 2016; 189:61-80. https://doi.org/10.1016/j.jep.2016.05.025.

[22] Luo MH, Zhao JL, Xu NJ, et al. Comparative efficacy of Xianling Gubao Capsules in improving bone mineral density in postmenopausal osteoporosis: a network meta-analysis. Front Endocrinol (Lausanne). 2022; 13:839885. https://doi.org/10.3389/fendo.2022.839885.

[23] Wei X, Qi B, Ma R, et al. Quantitative proteomics revealed the pharmacodynamic network of Bugu Shengsui Decoction promoting osteoblast proliferation. Front Endocrinol (Lausanne). 2021; 12:833474. https://doi.org/10.3389/fendo.2021.833474.

[24] Dai X, Liu Y, Liu T, et al. SiJunZi decoction ameliorates bone quality and redox homeostasis and regulates advanced glycation end products/receptor for advanced glycation end products and WNT/β-catenin signaling pathways in diabetic mice. J Ethnopharmacol. 2024; 319(Pt 2):117167. https://doi.org/10.1016/j.jep.2023.117167.

[25] Li C, Lin X, Lin Q, et al. Jiangu Granules ameliorate postmenopausal osteoporosis via rectifying bone homeostasis imbalance: a network pharmacology analysis based on multi-omics validation. Phytomedicine. 2024; 122:155137. https://doi.org/10.1016/j.phymed.2023.155137.

[26] Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res. 2010; 339(1):189-195. https://doi.org/10.1007/s00441-009-0832-8.

[27] Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002; 108(1):17-29. https://doi.org/10.1016/s0092-8674(01)00622-5.

[28] Kitase Y, Prideaux M.Targeting osteocytes vs osteoblasts. Bone. 2023; 170:116724. https://doi.org/10.1016/j.bone.2023.116724.

[29] Xue L, Jiang Y, Han T, et al. Comparative proteomic and metabolomic analysis reveal the antiosteoporotic molecular mechanism of icariin from Epimedium brevicornu Maxim. J Ethnopharmacol. 2016; 192:370-381. https://doi.org/10.1016/j.jep.2016.07.037.

[30] Liu J, Li D, Sun X, et al. Icariine restores LPS-induced bone loss by downregulating miR-34c level. Inflammation. 2016; 39(5):1764-1770. https://doi.org/10.1007/s10753-016-0411-6.

[31] Kong X, Wang F, Niu Y, et al. A comparative study on the effect of promoting the osteogenic function of osteoblasts using isoflavones from Radix Astragalus. Phytother Res. 2018; 32(1):115-124. https://doi.org/10.1002/ptr.5955.

[32] Wu J, Zeng Z, Li Y, et al. Cycloastragenol protects against glucocorticoid‐induced osteogenic differentiation inhibition by activating telomerase. Phytother Res. 2021; 35(4):2034-2044. https://doi.org/10.1002/ptr.6946.

[33] Park E, Kim J, Yeo S, et al. Anti-osteoporotic effects of combined extract of Lycii Radicis Cortex and Achyranthes japonica in osteoblast and osteoclast cells and ovariectomized mice. Nutrients. 2019; 11(11):2716. https://doi.org/10.3390/nu11112716.

[34] Park E, Kim J, Kim M, et al. Anti-osteoporotic effects of kukoamine B isolated from Lycii Radicis Cortex extract on osteoblast and osteoclast cells and ovariectomized osteoporosis model mice. Int J Mol Sci. 2019; 20(11):2784. https://doi.org/10.3390/ijms20112784.

[35] Park E, Kim J, Jin H, et al. Scopolin attenuates osteoporotic bone loss in ovariectomized mice. Nutrients. 2020; 12(11):3565. https://doi.org/10.3390/nu12113565.

[36] Park E, Lee CG, Lim E, et al. Osteoprotective effects of loganic acid on osteoblastic and osteoclastic cells and osteoporosis-induced mice. Int J Mol Sci. 2021; 22(1):233. https://doi.org/10.3390/ijms22010233.

[37] Liu H, Zhang H, Fan H, et al. The preventive effect of Cuscutae Semen polysaccharide on bone loss in the ovariectomized rat model. Biomed Pharmacother. 2020; 130:110613. https://doi.org/10.1016/j.biopha.2020.110613.

[38] Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5):1202-1209. https://doi.org/10.1172/JCI28551.

[39] Salhotra A, Shah HN, Levi B, et al. Mechanisms of bone development and repair. Nat Rev Mol Cell Biol. 2020; 21(11):696-711. https://doi.org/10.1038/s41580-020-00279-w.

[40] Sun Z, Jin H, Zhou H, et al. Guhong Injection promotes fracture healing by activating Wnt/β-catenin signaling pathway in vivo and in vitro. Biomed Pharmacother. 2019; 120:109436. https://doi.org/10.1016/j.biopha.2019.109436.

[41] Yun HM, Park KR, Quang TH, et al. 2,4,5-Trimethoxyldalbergiquinol promotes osteoblastic differentiation and mineralization via the BMP and Wnt/β-catenin pathway. Cell Death Dis. 2015; 6(7):e1819. https://doi.org/10.1038/cddis.2015.185.

[42] Hu J, Mao Z, He S, et al. Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling pathway. Biochem Pharmacol. 2017; 136:109-121. https://doi.org/10.1016/j.bcp.2017.04.010.

[43] Wang Q, Chen D, Jin H, et al. Hymenialdisine: a marine natural product that acts on both osteoblasts and osteoclasts and prevents estrogen-dependent bone loss in mice. J Bone Miner Res. 2020; 35(8):1582-1596. https://doi.org/10.1002/jbmr.4025.

[44] Mishra R, Das N, Varshney R, et al. Betel leaf extract and its major component hydroxychavicol promote osteogenesis and alleviate glucocorticoid-induced osteoporosis in rats. Food Funct. 2021; 12(14):6603-6625. https://doi.org/10.1039/D0FO02619K.

[45] Park KR, Lee JY, Cho M, et al. Biological mechanisms of paeonoside in the differentiation of pre-osteoblasts and the formation of mineralized nodules. Int J Mol Sci. 2021; 22(13):6899. https://doi.org/10.3390/ijms22136899.

[46] Zhu Y, Wang Y, Jia Y, et al. Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/β-catenin pathway. Stem Cell Res Ther. 2019; 10(1):37. https://doi.org/10.1186/s13287-019-1143-y.

[47] Li K, Zhang X, He B, et al. Geraniin promotes osteoblast proliferation and differentiation via the activation of Wnt/β-catenin pathway. Biomed Pharmacother. 2018; 99:319-324. https://doi.org/10.1016/j.biopha.2018.01.040.

[48] Xie CL, Yue YT, Xu JP, et al. Penicopeptide A (PPA) from the deep-sea-derived fungus promotes osteoblast-mediated bone formation and alleviates ovariectomy-induced bone loss by activating the AKT/GSK-3β/β-catenin signaling pathway. Pharmacol Res. 2023; 197:106968. https://doi.org/10.1016/j.phrs.2023.106968.

[49] Yu AX, Xu ML, Yao P, et al. Corylin, a flavonoid derived from Psoralea Fructus, induces osteoblastic differentiation via estrogen and Wnt/β-catenin signaling pathways. FASEB J. 2020; 34(3):4311-4328. https://doi.org/10.1096/fj.201902319RRR.

[50] Kim JH, Kim M, Hong S, et al. Albiflorin promotes osteoblast differentiation and healing of rat femoral fractures through enhancing BMP-2/Smad and Wnt/β-catenin signaling. Front Pharmacol. 2021; 12:690113. https://doi.org/10.3389/fphar.2021.690113.

[51] Hong S, Cha KH, Kwon DY, et al. Agastache rugosa ethanol extract suppresses bone loss via induction of osteoblast differentiation with alteration of gut microbiota. Phytomedicine. 2021; 84:153517. https://doi.org/10.1016/j.phymed.2021.153517.

[52] Wang X, Tian Y, Liang X, et al. Bergamottin promotes osteoblast differentiation and bone formation via activating the Wnt/β-catenin signaling pathway. Food Funct. 2022; 13(5):2913-2924. https://doi.org/10.1039/d1fo02755g.

[53] Lowery JW, Rosen V. The BMP pathway and its inhibitors in the skeleton. Physiol Rev. 2018; 98(4):2431-2452. https://doi.org/10.1152/physrev.00028.2017.

[54] Wang JY, Chen WM, Wen CS, et al. Du-Huo-Ji-Sheng-Tang and its active component Ligusticum chuanxiong promote osteogenic differentiation and decrease the aging process of human mesenchymal stem cells. J Ethnopharmacol. 2017; 198:64-72. https://doi.org/10.1016/j.jep.2016.12.011.

[55] Park KR, Kwon YJ, Park JE, et al. 7-HYB, a phenolic compound isolated from Myristica fragrans Houtt increases cell migration, osteoblast differentiation, and mineralization through BMP2 and β-catenin signaling. Int J Mol Sci. 2020; 21(21):8059. https://doi.org/10.3390/ijms21218059.

[56] Rai R, Kumar S, Singh KB, et al. Extract and fraction of Musa paradisiaca flower have osteogenic effect and prevent ovariectomy induced osteopenia. Phytomedicine. 2021; 93:153750. https://doi.org/10.1016/j.phymed.2021.153750.

[57] Hong S, Cha KH, Park JH, et al. Cinnamic acid suppresses bone loss via induction of osteoblast differentiation with alteration of gut microbiota. J Nutr Biochem. 2022; 101:108900. https://doi.org/10.1016/j.jnutbio.2021.108900.

[58] Sun C, Chen X, Yang S, et al. LBP1C-2 from Lycium barbarum alleviated age-related bone loss by targeting BMPRIA/BMPRII/Noggin. Carbohydr Polym. 2023; 310:120725. https://doi.org/10.1016/j.carbpol.2023.120725.

[59] Park JH, Son YJ, Lee CH, et al. Circaea mollis Siebold & Zucc. alleviates postmenopausal osteoporosis in a mouse model via the BMP-2/4/Runx2 pathway. BMC Complement Med Ther. 2020; 20(1):123. https://doi.org/10.1186/s12906-020-02914-7.

[60] Wan HW, Chin KY, Abd GN, et al. Annatto-derived tocotrienol promotes mineralization of MC3T3-E1 cells by enhancing BMP-2 protein expression via inhibiting RhoA activation and HMG-CoA reductase gene expression. Drug Des Devel Ther. 2020; 14:969-976. https://doi.org/10.2147/DDDT.S224941.

[61] Greenblatt MB, Shim JH, Glimcher LH. Mitogen-activated protein kinase pathways in osteoblasts. Annu Rev Cell Dev Biol. 2013; 29:63-79. https://doi.org/10.1146/annurev-cellbio-101512-122347.

[62] Seo BK, Ryu HK, Park YC, et al. Dual effect of WIN-34B on osteogenesis and osteoclastogenesis in cytokine-induced mesenchymal stem cells and bone marrow cells. J Ethnopharmacol. 2016; 193:227-236. https://doi.org/10.1016/j.jep.2016.07.022.

[63] Zha X, Xu Z, Liu Y, et al. Amentoflavone enhances osteogenesis of human mesenchymal stem cells through JNK and p 38 MAPK pathways. J Nat Med. 2016; 70(3):634-644. https://doi.org/10.1007/s11418-016-0993-1.

[64] Liu L, Wang D, Qin Y, et al. Astragalin promotes osteoblastic differentiation in MC3T3-E1 cells and bone formation in vivo. Front Endocrinol (Lausanne). 2019; 10:228. https://doi.org/10.3389/fendo.2019.00228.

[65] Su Z, Chen D, Huang J, et al. Isoliquiritin treatment of osteoporosis by promoting osteogenic differentiation and autophagy of bone marrow mesenchymal stem cells. Phytother Res. 2024; 38(1):214-230. https://doi.org/10.1002/ptr.8032.

[66] Jeon EJ, Lee DH, Kim YJ, et al. Effects of yuja peel extract and its flavanones on osteopenia in ovariectomized rats and osteoblast differentiation. Mol Nutr Food Res. 2016; 60(12):2587-2601. https://doi.org/10.1002/mnfr.201600257.

[67] Sun K, Luo J, Guo J, et al. The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthr Cartil. 2020; 28(4):400-409. https://doi.org/10.1016/j.joca.2020.02.027.

[68] Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015; 14:137. https://doi.org/10.1186/s12943-015-0404-3.

[69] Zhang H, Zhou C, Zhang Z, et al. Integration of network pharmacology and experimental validation to explore the pharmacological mechanisms of Zhuanggu Busui Formula against osteoporosis. Front Endocrinol (Lausanne). 2021; 12:841668. https://doi.org/10.3389/fendo.2021.841668.

[70] Wu CM, Chen PC, Li TM, et al. Si-Wu-Tang extract stimulates bone formation through PI3K/Akt/NF-κB signaling pathways in osteoblasts. BMC Complement Altern Med. 2013; 13:277. https://doi.org/10.1186/1472-6882-13-277.

[71] Ke K, Li Q, Yang X, et al. Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model. Sci Rep. 2016; 6:35233. https://doi.org/10.1038/srep35233.

[72] Huang L, Wang X, Cao H, et al. A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice. Biomaterials. 2018; 182:58-71. https://doi.org/10.1016/j.biomaterials.2018.07.046.

[73] Liu H, Li X, Lin J, et al. Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. Biosci Biotechnol Biochem. 2021; 85(2):332-339. https://doi.org/10.1093/bbb/zbaa010.

[74] Dong XL, Yu WX, Li CM, et al. Chuanxiong (rhizome of Ligusticum chuanxiong) protects ovariectomized hyperlipidemic rats from bone loss. Am J Chin Med. 2020; 48(2):463-485. https://doi.org/10.1142/S0192415X2050024X.

[75] Fontani F, Marcucci G, Iantomasi T, et al. Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/ 2 signalling. Calcif Tissue Int. 2015; 96(4):335-346. https://doi.org/10.1007/s00223-015-9961-0.

[76] Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Joint Surg Am. 2021; 103(15):1451-1461. https://doi.org/10.2106/JBJS.20.00989.

[77] Motoyama T, Okamoto K, Kukita I, et al. Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndrome. Crit Care Med. 2003; 31(4):1048-1052. https://doi.org/10.1097/01.CCM.0000055371.27268.36.

[78] Qin D, Zhang H, Zhang H, et al. Anti-osteoporosis effects of osteoking via reducing reactive oxygen species. J Ethnopharmacol. 2019; 244:112045. https://doi.org/10.1016/j.jep.2019.112045.

[79] Jing Z, Wang C, Yang Q, et al. Luteolin attenuates glucocorticoid-induced osteoporosis by regulating ERK/Lrp-5/GSK-3β signaling pathway in vivo and in vitro. J Cell Physiol. 234(4):4472-4490. https://doi.org/10.1002/jcp.27252.

[80] Phromnoi K, Yodkeeree S, Pintha K, et al. Anti-osteoporosis effect of Perilla frutescens leaf hexane fraction through regulating osteoclast and osteoblast differentiation. Molecules. 2022; 27(3):824. https://doi.org/10.3390/molecules27030824.

[81] Zhang JK, Yang L, Meng GL, et al. Protection by salidroside against bone loss via inhibition of oxidative stress and bone-resorbing mediators. PLoS One. 2013; 8(2):e57251. https://doi.org/10.1371/journal.pone.0057251.

[82] Huang Q, Gao B, Jie Q, et al. Ginsenoside-Rb2 displays anti-osteoporosis effects through reducing oxidative damage and bone-resorbing cytokines during osteogenesis. Bone. 2014; 66:306-314. https://doi.org/10.1016/j.bone.2014.06.010.

[83] Huang Q, Shi J, Gao B, et al. Gastrodin: an ancient Chinese herbal medicine as a source for anti-osteoporosis agents via reducing reactive oxygen species. Bone. 2015; 73:132-144. https://doi.org/10.1016/j.bone.2014.12.059.

[84] Huang Q, Gao B, Wang L, et al. Ophiopogonin D: a new herbal agent against osteoporosis. Bone. 2015; 74:18-28. https://doi.org/10.1016/j.bone.2015.01.002.

[85] Luo S, Yang Y, Chen J, et al. Tanshinol stimulates bone formation and attenuates dexamethasone-induced inhibition of osteogenesis in larval zebrafish. J Orthop Translat. 2016; 4:35-45. https://doi.org/10.1016/j.jot.2015.07.002.

[86] Casati L, Pagani F, Fibiani M, et al. Potential of delphinidin-3-rutinoside extracted from Solanum melongena L. as promoter of osteoblastic MC3T3-E 1 function and antagonist of oxidative damage. Eur J Nutr. 2019; 58(3):1019-1032. https://doi.org/10.1007/s00394-018-1618-0.

[87] Li X, Lin H, Zhang X, et al. Notoginsenoside R1 attenuates oxidative stress-induced osteoblast dysfunction through JNK signalling pathway. J Cell Mol Med. 2021; 25(24):11278-11289. https://doi.org/10.1111/jcmm.17054.

[88] Hu HY, Zhang ZZ, Jiang XY, et al. Hesperidin anti-osteoporosis by regulating estrogen signaling pathways. Molecules. 2023; 28(19):6987. https://doi.org/10.3390/molecules28196987.

[89] Li Z, Li D, Su H, et al. Autophagy: an important target for natural products in the treatment of bone metabolic diseases. Front Pharmacol. 2022; 13:999017. https://doi.org/10.3389/fphar.2022.999017.

[90] Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018; 19(6):349-364. https://doi.org/10.1038/s41580-018-0003-4.

[91] Wang J, Zhang Y, Cao J, et al. The role of autophagy in bone metabolism and clinical significance. Autophagy. 2023; 19(9):2409-2427. https://doi.org/10.1080/15548627.2023.2186112.

[92] Ceccariglia S, Cargnoni A, Silini AR, et al. Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells. Autophagy. 2020; 16(1):28-37. https://doi.org/10.1080/15548627.2019.1630223.

[93] Ma Y, Qi M, An Y, et al. Autophagy controls mesenchymal stem cell properties and senescence during bone aging. Aging Cell. 2018; 17(1):e12709. https://doi.org/10.1111/acel.12709.

[94] Li H, Li D, Ma Z, et al. Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss. Autophagy. 2018; 14(10):1726-1741. https://doi.org/10.1080/15548627.2018.1483807.

[95] Weng YM, Ke CR, Kong JZ, et al. The significant role of ATG5 in the maintenance of normal functions of Mc3T3-E1 osteoblast. Eur Rev Med Pharmacol Sci. 2018; 22(5):1224-1232. https://doi.org/10.26355/eurrev_201803_14462.

[96] Nollet M, Santucci-Darmanin S, Breuil V, et al. Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy. 2014; 10(11):1965-1977. https://doi.org/10.4161/auto.36182.

[97] Zhao B, Peng Q, Poon E, et al. Leonurine promotes the osteoblast differentiation of rat BMSCs by activation of autophagy via the PI3K/Akt/mTOR pathway. Front Bioeng Biotechnol. 2021; 9:615191. https://doi.org/10.3389/fbioe.2021.615191.

[98] Zhao B, Peng Q, Wang D, et al. Leonurine protects bone mesenchymal stem cells from oxidative stress by activating mitophagy through PI3K/Akt/mTOR pathway. Cells. 2022; 11(11):1724. https://doi.org/10.3390/cells11111724.

[99] Zheng X, Yu Y, Shao B, et al. Osthole improves therapy for osteoporosis through increasing autophagy of mesenchymal stem cells. Exp Anim. 2019; 68(4):453-463. https://doi.org/10.1538/expanim.18-0178.

[100] Zhang Y, Li M, Liu Z, et al. Arbutin ameliorates glucocorticoid-induced osteoporosis through activating autophagy in osteoblasts. Exp Biol Med (Maywood). 2021; 246(14):1650-1659. https://doi.org/10.1177/15353702211002136.

[101] Zhang X, Huang F, Chen X, et al. Ginsenoside Rg 3 attenuates ovariectomy-induced osteoporosis via AMPK/mTOR signaling pathway. Drug Dev Res. 2020; 81(7):875-884. https://doi.org/10.1002/ddr.21705.

[102] Shi Y, Liu XY, Jiang YP, et al. Monotropein attenuates oxidative stress via Akt/mTOR-mediated autophagy in osteoblast cells. Biomed Pharmacother. 2020; 121:109566. https://doi.org/10.1016/j.biopha.2019.109566.

[103] Liang X, Hou Z, Xie Y, et al. Icariin promotes osteogenic differentiation of bone marrow stromal cells and prevents bone loss in OVX mice via activating autophagy. J Cell Biochem. 2019; 120(8):13121-13132. https://doi.org/10.1002/jcb.28585.

[104] Bai L, Liu Y, Zhang X, et al. Osteoporosis remission via an anti-inflammaging effect by icariin activated autophagy. Biomaterials. 2023; 297:122125. https://doi.org/10.1016/j.biomaterials.2023.122125.

[105] Wang N, Xu P, Wu R, et al. Timosaponin BII improved osteoporosis caused by hyperglycemia through promoting autophagy of osteoblasts via suppressing the mTOR/NFκB signaling pathway. Free Radic Biol Med. 2021; 171:112-123. https://doi.org/10.1016/j.freeradbiomed.2021.05.014.

[106] Park KR, Kim B, Lee JY, et al. Effects of scoparone on differentiation, adhesion, migration, autophagy and mineralization through the osteogenic signalling pathways. J Cell Mol Med. 2022; 26(16):4520-4529. https://doi.org/10.1111/jcmm.17476.

[107] Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. Nature. 2019; 571(7766):489-499. https://doi.org/10.1038/s41586-019-1411-0.

[108] Ghayor C, Weber F. Epigenetic regulation of bone remodeling and its impacts in osteoporosis. Int J Mol Sci. 2016; 17(9):1446. https://doi.org/10.3390/ijms17091446.

[109] Reppe S, Datta H, Gautvik K. The influence of DNA methylation on bone cells. Curr Genomics. 2015; 16(6):384-392. https://doi.org/10.2174/1389202916666150817202913.

[110] Martin SL, Hardy TM, Tollefsbol TO. Medicinal chemistry of the epigenetic diet and caloric restriction. Curr Med Chem. 2013; 20(32):4050-4059. https://doi.org/10.2174/09298673113209990189.

[111] Husain A, Jeffries MA. Epigenetics and bone remodeling. Curr Osteoporos Rep. 2017; 15(5):450-458. https://doi.org/10.1007/s11914-017-0391-y.

[112] Visconti VV, Cariati I, Fittipaldi S, et al. DNA methylation signatures of bone metabolism in osteoporosis and osteoarthritis aging-related diseases: an updated review. Int J Mol Sci. 2021; 22(8):4244. https://doi.org/10.3390/ijms22084244.

[113] Altaf M, Saksouk N, Côté J. Histone modifications in response to DNA damage. Mutat Res. 2007; 618(1-2):81-90. https://doi.org/10.1016/j.mrfmmm.2006.09.009.

[114] Widmayer P, Xu Y, Zhu B. Combinatorial optimization and applications. Theor Comput Sci. 2014; 556:1. https://doi.org/10.1016/j.tcs.2014.09.047.

[115] Li CJ, Cheng P, Liang MK, et al. microRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015; 125(4):1509-1522. https://doi.org/10.1172/JCI77716.

[116] Nabeshima T, Tsukamoto M, Wang KY, et al. Delayed cortical bone healing due to impaired nuclear Nrf2 translocation in COPD mice. Bone. 2023; 173:116804. https://doi.org/10.1016/j.bone.2023.116804.

[117] Raut N, Wicks SM, Lawal TO, et al. Epigenetic regulation of bone remodeling by natural compounds. Pharmacol Res. 2019; 147:104350. https://doi.org/10.1016/j.phrs.2019.104350.

[118] Thaler R, Maurizi A, Roschger P, et al. Anabolic and antiresorptive modulation of bone homeostasis by the epigenetic modulator sulforaphane, a naturally occurring isothiocyanate. J Biol Chem. 2016; 291(13):6754-6771. https://doi.org/10.1074/jbc.M115.678235.

[119] Behera J, Ison J, Rai H, et al. Allyl sulfide promotes osteoblast differentiation and bone density via reducing mitochondrial DNA release mediated Kdm6b/H3K27me3 epigenetic mechanism. Biochem Biophys Res Commun. 2021; 543:87-94. https://doi.org/10.1016/j.bbrc.2021.01.016.

[120] Ornstrup MJ, Harsløf T, Kjær TN, et al. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014; 99(12):4720-4729. https://doi.org/10.1210/jc.2014-2799.

[121] Bo S, Gambino R, Ponzo V, et al. Effects of resveratrol on bone health in type 2 diabetic patients A double-blind randomized-controlled trial. Nutr Diabetes. 2018; 8(1):51. https://doi.org/10.1038/s41387-018-0059-4.

[122] Bäckesjö CM, Li Y, Lindgren U, et al. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J Bone Miner Res. 2006; 21(7):993-1002. https://doi.org/10.1359/jbmr.060415.

[123] Danks L, Komatsu N, Guerrini MM, et al. RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. Ann Rheum Dis. 2016; 75(6):1187-1195. https://doi.org/10.1136/annrheumdis-2014-207137.

[124] Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-κB ligand (RANKL) activation of NF-κB signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem. 2011; 286(13):11492-11505. https://doi.org/10.1074/jbc.M110.198713.

[125] Ali D, Chen L, Kowal JM, et al. Resveratrol inhibits adipocyte differentiation and cellular senescence of human bone marrow stromal stem cells. Bone. 2020; 133:115252. https://doi.org/10.1016/j.bone.2020.115252.

[126] Wang H, Hu Z, Wu J, et al. Sirt1 promotes osteogenic differentiation and increases alveolar bone mass via Bmi1 activation in mice. J Bone Miner Res. 2019; 34(6):1169-1181. https://doi.org/10.1002/jbmr.3677.

[127] Jiang Y, Luo W, Wang B, et al. Resveratrol promotes osteogenesis via activating SIRT1/FoxO1 pathway in osteoporosis mice. Life Sci. 2020; 246:117422. https://doi.org/10.1016/j.lfs.2020.117422.

[128] Ghorbaninejad M, Khademi-Shirvan M, Hosseini S, et al. Effective role of curcumin on expression regulation of EZH2 histone methyltransferase as a dynamic epigenetic factor in osteogenic differentiation of human mesenchymal stem cells. Biochim Biophys Acta Gene Regul Mech. 2023; 1866(1): 194903. https://doi.org/10.1016/j.bbagrm.2022.194903.

[129] Arumugam B, Balagangadharan K, Selvamurugan N. Syringic acid, a phenolic acid, promotes osteoblast differentiation by stimulation of Runx 2 expression and targeting of Smad7 by miR-21 in mouse mesenchymal stem cells. J Cell Commun Signal. 2018; 12(3):561-573. https://doi.org/10.1007/s12079-018-0449-3.

[130] Tanaka T, Kawaguchi N, Zaima N, et al. Antiosteoporotic activity of a syringic acid diet in ovariectomized mice. J Nat Med. 2017; 71(4):632-641. https://doi.org/10.1007/s11418-017-1105-6.

[131] Teng JW, Bian SS, Kong P, et al. Icariin triggers osteogenic differentiation of bone marrow stem cells by up-regulating miR-335-5p. Exp Cell Res. 2022; 414(2):113085. https://doi.org/10.1016/j.yexcr.2022.113085.

[132] Zhan XQ, Zeng XW, Zhang YY, et al. Puerarin promotes the viability and differentiation of MC3T3-E 1 cells by miR-204-regulated Runx2 upregulation. Mol Med Rep. 2017; 16(5):6262-6268. https://doi.org/10.3892/mmr.2017.7386.

[133] Liu H, Yi X, Tu S, et al. Kaempferol promotes BMSC osteogenic differentiation and improves osteoporosis by downregulating miR-10a-3p and upregulating CXCL12. Mol Cell Endocrinol. 2021; 520:111074. https://doi.org/10.1016/j.mce.2020.111074.

[134] Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017; 97(1):135-187. https://doi.org/10.1152/physrev.00033.2015.

[135] Wang Y, Wang WL, Xie WL, et al. Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation. Phytomedicine. 2013; 20(10):787-796. https://doi.org/10.1016/j.phymed.2013.03.005.

[136] Zhao Y, Xu Y, Zheng H, et al. QingYan Formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways. J Ethnopharmacol. 2021; 268:113644. https://doi.org/10.1016/j.jep.2020.113644.

[137] Wu QC, Tang XY, Dai ZQ, et al. Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p 38 signalling pathway on MC3T3-E1 cells. Phytomedicine. 2020; 68:153146. https://doi.org/10.1016/j.phymed.2019.153146.

[138] Zhou L, Poon CC, Wong KY, et al. Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling. Phytomedicine. 2021; 82:153413. https://doi.org/10.1016/j.phymed.2020.153413.

[139] Chen Q, Shou P, Zheng C, et al. Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ. 2016; 23(7):1128-1139. https://doi.org/10.1038/cdd.2015.168.

[140] Park E, Lim E, Yeo S, et al. Anti-menopausal effects of Cornus officinalis and Ribes fasciculatum extract in vitro and in vivo. Nutrients. 2020; 12(2):369. https://doi.org/10.3390/nu12020369.

[141] Ko CH, Siu WS, Wong HL, et al. Pro-bone and antifat effects of green tea and its polyphenol, epigallocatechin, in rat mesenchymal stem cells in vitro. J Agric Food Chem. 2011; 59(18):9870-9876. https://doi.org/10.1021/jf202015t.

[142] Peng H, Yang M, Guo Q, et al. Dendrobium officinale polysaccharides regulate age-related lineage commitment between osteogenic and adipogenic differentiation. Cell Prolif. 2019; 52(4):e12624. https://doi.org/10.1111/cpr.12624.

[143] An J, Yang H, Zhang Q, et al. Natural products for treatment of osteoporosis: the effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016; 147:46-58. https://doi.org/10.1016/j.lfs.2016.01.024.

[144] Yao H, Liu J, Xu S, et al. The structural modification of natural products for novel drug discovery. Expert Opin Drug Discov. 2017; 12(2):121-140. https://doi.org/10.1080/17460441.2016.1272757.

[145] Wani TU, Khan RS, Rather AH, et al. Local dual delivery therapeutic strategies: using biomaterials for advanced bone tissue regeneration. J Control Release. 2021; 339:143-155. https://doi.org/10.1016/j.jconrel.2021.09.029.

[146] Mora-Raimundo P, Lozano D, Benito M, et al. Osteoporosis remission and new bone formation with mesoporous silica nanoparticles. Adv Sci (Weinh). 2021; 8(16):e2101107. https://doi.org/10.1002/advs.202101107.

[147] Yousefzadeh N, Kashfi K, Jeddi S, et al. Ovariectomized rat model of osteoporosis: a practical guide. EXCLI J. 2020; 19:89-107. https://doi.org/10.17179/excli2019-1990.

[148] Sophocleous A, Idris AI. Rodent models of osteoporosis. Bonekey Rep. 2014; 3:614. https://doi.org/10.1038/bonekey.2014.109.

[149] Xavier A, Toumi H, Lespessailles E. Animal model for glucocorticoid induced osteoporosis: a systematic review from 2011 to 2021. Int J Mol Sci. 2021; 23(1):377. https://doi.org/10.3390/ijms23010377.

[150] Dietrich K, Fiedler IA, Kurzyukova A, et al. Skeletal biology and disease modeling in zebrafish. J Bone Miner Res. 2021; 36(3):436-458. https://doi.org/10.1002/jbmr.4256.

[151] Lleras-Forero L, Winkler C, Schulte-Merker S. Zebrafish and medaka as models for biomedical research of bone diseases. Dev Biol. 2020; 457(2):191-205. https://doi.org/10.1016/j.ydbio.2019.07.009.

[152] Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021; 20(8):611-628. https://doi.org/10.1038/s41573-021-00210-8.

[153] Ma J, Chen Y, Song J, et al. Establishment and application of a zebrafish model of Werner syndrome identifies sapanisertib as a potential antiaging drug. Proc Natl Acad Sci U S A. 2025; 122(5):e2413719122. https://doi.org/10.1073/pnas.2413719122.

[154] Tan L, Tu Y, Miao Z, et al. Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. Phytomedicine. 2025; 138:156429. https://doi.org/10.1016/j.phymed.2025.156429.

[155] Cui J, Shibata Y, Zhu T, et al. Osteocytes in bone aging: advances, challenges, and future perspectives. Ageing Res Rev. 2022; 77:101608. https://doi.org/10.1016/j.arr.2022.101608.

[156] Metzger TA, Kreipke TC, Vaughan TJ, et al. The in situ mechanics of trabecular bone marrow: the potential for mechanobiological response. J Biomech Eng. 2015; 137(1):28985. https://doi.org/10.1115/1.4028985.

[157] Chai S, Wan L, Wang JL, et al. Gushukang inhibits osteocyte apoptosis and enhances BMP-2/Smads signaling pathway in ovariectomized rats. Phytomedicine. 2019; 64:153063. https://doi.org/10.1016/j.phymed.2019.153063.

[158] Izzo AA, Hoon-Kim S, Radhakrishnan R, et al. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of herbal remedies. Phytother Res. 2016; 30(5):691-700. https://doi.org/10.1002/ptr.5591.